ロード中...

Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells

BACKGROUND: PD-1/PD-L1 blockade can confer durable benefits in the treatment of metastatic cancers, but the response rate remains modest and potential adverse effects occur sometimes. Concentrating immunotherapeutic agents at the site of disease was believed to break local immune tolerance and reduc...

詳細記述

保存先:
書誌詳細
出版年:J Hematol Oncol
主要な著者: Yang, Yuanyuan, Zhang, Xiaolong, Lin, Fangzhen, Xiong, Mengshang, Fan, Dongmei, Yuan, Xiangfei, Lu, Yang, Song, Yuewen, Zhang, Yizi, Hao, Mu, Ye, Zhou, Zhang, Yanjun, Wang, Jianxiang, Xiong, Dongsheng
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2019
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482514/
https://ncbi.nlm.nih.gov/pubmed/31023384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0723-8
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!